Under a tenth of individuals that would benefit from GLP-1 drugs like Wegovy can access them, caution the World Health Organization as it issues its inaugural advice on the medications.
Given more than one billion individuals worldwide now classified as obese, it is advocating for increased and just availability to GLP-1 medication.
According to projections, in excess of 2,000,000,000 could be obese by 2030 without intervention.
"Our latest guidelines recognises that obesity is a lifelong illness that can be addressed with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and logistical bottlenecks are major hurdles to broad access to the treatments that can assist patients in reducing significant weight, explains the agency.
Skinny Jab Scarcity
Even in the current most favorable case, the production of GLP-1 therapies might only reach about 100 million people – less than 10% of the global need, per the health organization.
The recommendation calls on countries and companies to increase access, through strategies like licensing agreements.
A patent on semaglutide – the primary ingredient of the drug Wegovy – is scheduled to end in several nations in 2026.
How Obesity Jabs Function
The injections mimick a biological compound to reduce digestion speed, curb appetite and enhance feelings of fullness so users reduce food intake.
Patients usually see weight reduction within a few weeks of commencing the weekly injections.
Research indicates users may regain a significant portion within a year of stopping the medication, when their usual food cravings resume.
To be carrying excess weight elevates your chance for developing health problems, including diabetes, cardiovascular issues, brain attack, and specific malignancies.
Obesity concerns people in all nations and was associated with 3.7 million fatalities worldwide in 2024, according to the health agency.
